Oncogenic signals as treatment targets in classic myeloproliferative neoplasms. Review uri icon

Overview

MeSH Major

  • Myeloproliferative Disorders
  • Oncogene Proteins

abstract

  • Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions. Other MPN-relevant putative oncogenes that are awaiting therapeutic validation, include JAK2 and MPL mutations in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF); KITD816V and other KIT mutations in systemic mastocytosis, and FGFR1 rearrangements associated with the 8p11 leukemia/lymphoma syndrome. The current review focuses on mutant molecules of interest in classic MPNs (ie, CML, PV, ET, and PMF) in the context of their value as drug targets.

publication date

  • March 2, 2009

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 19147089

Additional Document Info

start page

  • 114

end page

  • 9

volume

  • 15

number

  • 1 Suppl